Totaligent extends GloMed deal timeline to April 2026

Totaligent, Inc. entered into an Extension Amendment to its Binding Letter of Intent with GloMed Solutions Limited Liability Company dated February 22, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Totaligent, Inc. entered into an Extension Amendment to its Binding Letter of Intent with GloMed Solutions Limited Liability Company dated February 22, 2026. The original letter outlines plans for a joint venture and a call option for Totaligent to acquire GloMed, including its operations, intellectual property, and related assets.

The Amendment moves the target dates for negotiating and signing definitive agreements, and for closing the proposed transaction, to April 22, 2026 to allow more time for negotiations and due diligence. The binding exclusivity period is also extended through April 22, 2026, with all other terms of the letter of intent remaining in effect.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Totaligent (TGNT) change in its agreement with GloMed?

Totaligent signed an Extension Amendment to its Binding Letter of Intent with GloMed. This pushes back the target dates for negotiating, signing, and closing definitive joint venture and acquisition documents to April 22, 2026, while keeping all other LOI terms in place.

What is the purpose of Totaligent’s proposed transaction with GloMed?

The proposed transaction contemplates forming a joint venture and giving Totaligent a call option to acquire GloMed. That acquisition would include GloMed’s business operations, intellectual property, and related assets, subject to negotiation and execution of definitive agreements described in the letter of intent.

How long is the exclusivity period between Totaligent and GloMed now?

The binding exclusivity period in the letter of intent has been extended through April 22, 2026. It remains subject to earlier termination as provided in the original LOI, but otherwise continues unchanged under the Extension Amendment executed on March 22, 2026.

Did the Extension Amendment change other terms of the GloMed LOI for TGNT?

The Extension Amendment only adjusts timing and related exclusivity; all other LOI terms stay in effect. It does not alter the contemplated joint venture structure, the call option concept, or the types of definitive agreements expected, such as asset contribution and intellectual property assignment agreements.

When is Totaligent now targeting to close the GloMed transaction?

Totaligent and GloMed now target April 22, 2026 for closing the proposed transaction. This new date gives both parties extra time for due diligence and negotiation of definitive joint venture, asset contribution, and intellectual property assignment agreements described in the Binding Letter of Intent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/26/2026 - 06:51 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 22, 2026

TOTALIGENT, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41803

80-0142655

(State or other

jurisdiction of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3651 FAU Boulevard, Suite 400

Boca Raton, Florida

33431

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (561) 360-3565

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12b of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange Registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On March 22, 2026, Totaligent, Inc. (the “Company”) entered into an Extension Amendment (the “Amendment”) to the Binding Letter of Intent dated February 22, 2026 (the “LOI”) with GloMed Solutions Limited Liability Company (“GloMed”). As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 23, 2026, the LOI sets forth the principal terms for a proposed transaction pursuant to which the Company and GloMed would form a joint venture and the Company would receive a call option to acquire GloMed, including its business operations, intellectual property, and related assets.

The Amendment extends the target date for the negotiation and execution of definitive agreements (including, but not limited to, joint venture agreements, asset contribution agreements, intellectual property assignment agreements, and related transaction documents), and the target closing date of the transaction, to April 22, 2026, to allow additional time for completion of negotiations and due diligence. The binding exclusivity period set forth in the LOI has been extended through April 22, 2026, or such earlier date as provided in the LOI, and is not affected by the Amendment. Except as expressly amended, all terms and conditions of the LOI remain in full force and effect.

The foregoing description is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

10.1		Extension Amendment to Binding Letter of Intent, dated March 22, 2026, between Totaligent, Inc. and GloMed Solutions Limited Liability Company.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TOTALIGENT, INC.

Date: March 26, 2026	By:	/s/ EDWARD C DEFEUDIS
		Edward C. DeFeudis CEO

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

6 documents

Agreements & Contracts

EX-10.1 EXTENSION AMENDMENT 9.8 KB